{"id":"NCT00724867","sponsor":"Human Genome Sciences Inc., a GSK Company","briefTitle":"A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States","officialTitle":"A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2008-07-30","resultsPosted":"2016-03-28","lastUpdate":"2016-03-28"},"enrollment":268,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"BIOLOGICAL","name":"Belimumab 1 mg/kg","otherNames":["BENLYSTA","HGS1006","LymphoStat-B™"]},{"type":"BIOLOGICAL","name":"Belimumab 10 mg/kg","otherNames":["LymphoStat-B™","BENLYSTA","HGS1006"]}],"arms":[{"label":"Belimumab 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Belimumab 10 mg/kg","type":"EXPERIMENTAL"}],"summary":"This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.","primaryOutcome":{"measure":"Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)","timeFrame":"Up to Week 440","effectByArm":[{"arm":"Belimumab 10 mg/kg IV","deltaMin":267,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":["30320964","29409143"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":112,"n":268},"commonTop":["Any event","Any event","Any event","Any event","Any event"]}}